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Biosensors with high sensitivity and short time-to-result that are capable of detecting biomarkers in
body ﬂuids such as serum are an important prerequisite for early diagnostics in modern healthcare
provision. Here, we report the development of an electrochemical impedance-based sensor for the de-
tection in serum of human interleukin-8 (IL-8), a pro-angiogenic chemokine implicated in a wide range
of inﬂammatory diseases. The sensor employs a small and robust synthetic non-antibody capture protein
based on a cystatin scaffold that displays high afﬁnity for human IL-8 with a KD of 35710 nM and
excellent ligand speciﬁcity. The change in the phase of the electrochemical impedance from the serum
baseline, Δθ(ƒ), measured at 0.1 Hz, was used as the measure for quantifying IL-8 concentration in the
ﬂuid. Optimal sensor signal was observed after 15 min incubation, and the sensor exhibited a linear
response versus logarithm of IL-8 concentration from 900 fg/ml to 900 ng/ml. A detection limit of around
90 fg/ml, which is signiﬁcantly lower than the basal clinical levels of 5–10 pg/ml, was observed. Our
results are signiﬁcant for the development of point-of-care and early diagnostics where high sensitivity
and short time-to-results are essential.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Modern healthcare systems rely heavily on in vitro diagnostics.
The ability to detect biomarkers in body ﬂuids at the point of care
with high sensitivity and short time-to-result is becoming critical
in a society placing increasing importance on both disease pre-
vention, early diagnostics, and on stratiﬁed and individualised
patient care. Interleukin-8 (IL-8; also referred to as CXCL8) is a
chemokine that plays a pivotal role in acute inﬂammations and
hence is an important biomarker for a range of diseases (Turner
et al., 2014). During an injury or infection IL-8 is involved in the
recruitment of neutrophils from blood vessels to the affected tis-
sue (Hammond et al., 1995) promoting angiogenesis (Li et al.,
2003). However, stimulants such as pro-inﬂammatory cytokines
(e.g. TNF-α and interleukin-1), cellular stress, or bacterial and viral
products, also trigger cells to express IL-8 proteins (Hoffmannr B.V. This is an open access article
d Cellular Biology, University
. McPherson),
ork.et al., 2002), activating neutrophils (Zeilhofer and Schorr, 2000;
Leung et al., 2001) that release their toxic intracellular contents
causing damage to host tissue and resulting in acute inﬂammation
states (Wright et al., 2010). Often, elevated IL-8 levels are also
associated with the progression of numerous chronic diseases in-
cluding rheumatoid arthritis, inﬂammatory bowel disease, psor-
iasis, palmoplantar pustulosis, idiopathic pulmonary ﬁbrosis, acute
respiratory distress syndrome (ARDS), atherosclerosis, central
nervous system trauma, development of malignant cancer, and
chronic liver disease (Mukaida, 2003; Skov et al., 2008; Waugh
and Wilson, 2008; Apostolakis et al., 2009; Zimmermann et al.,
2011). Therefore, the ability to monitor IL-8 concentrations with
high accuracy in body ﬂuids, e.g. serum, is an important pre-
requisite to enable early and accurate detection of severe illnesses,
some of which result in progressive deterioration and consequent
mortality.
Enzyme-linked immunosorbent assays (ELISAs) are currently
the de facto standard for detecting IL-8 proteins in clinical diag-
nostics applications (Korostoff et al., 2011; Elsalhy et al., 2013;
Necchi et al., 2014; Pedersen et al., 2015; Zhu et al., 2015). How-
ever, despite their widespread use, ELISA tests are limited in their
applicability for point-of-care (POC) use as they generally require
large and expensive instrumentation and additional reagents, areunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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limited in sensitivity (Daniels and Pourmand, 2007). In healthy
patients the IL-8 basal clinical level is 5–10 pg/ml (Benoy et al.,
2004), and although most of the commercially available IL-8 ELISA
kits state detection limits for human IL-8 of around 1575 pg/ml,
reproducible and reliable detection of small increases in con-
centrations in body ﬂuids, a prerequisite for reliable early detec-
tion, remains a signiﬁcant challenge. Alternative assays, such as
the ﬂuorescent-beads-based Luminex technology, are generally
used to screen for enhanced levels of IL-8 rather than for quanti-
tative measurements, mostly owing to reproducibility challenges
(Djoba Siawaya et al., 2008; Gubala et al., 2012). In addition, label-
free strategies for the detection of IL-8 were reported in the lit-
erature, including surface plasmon resonance (SPR)-based sensors
that yielded a detection limit of 1.65 ng/ml IL-8 in human saliva
(Yang et al., 2005). Recently, the detection of a few fg/ml of IL-8 in
serum was demonstrated using a multi-step indirect sandwich
immunoassay (Munge et al., 2011), where an electrode coated with
a dense ﬁlm of glutathione-protected gold nanoparticles modiﬁed
with primary antibodies was used to capture human IL-8. For
detection, super-paramagnetic beads coated with secondary anti-
bodies and horseradish peroxidase were employed. However,
time-to-result was a few hours, limiting their suitability for POC
testing. Hence, to facilitate accurate, rapid and reliable testing at
low cost to enable early diagnosis at POC, alternative approaches
are required.
Electrochemical impedance spectroscopy (EIS) has been shown
to provide a very promising biosensing approach with potentially
very low limits of detection and time-to-results of minutes rather
than hours. Examples offering limits of detection in the sub-pg/ml
region include EIS-based sensors for the detection of soluble
proteins such as IL-6, IL-2, and hCG (Berggren et al., 1998) and IFN-
γ (Dijksma et al., 2001), albeit in buffer solutions. A direct label-
free electrochemical biosensor for measuring IL-8 in clinical
samples such as full serum at or below basal clinical levels, i.e.
r5–10 pg/ml, has not been reported to date.
A typical EIS biosensor comprises a sensing element consisting
of a conducting surface onto which capture molecules are im-
mobilised which recognise and bind to the target protein of in-
terest. The most widely employed capture molecules are anti-
bodies. However, their interaction with solid surfaces can com-
promise their stability, which can lead to a loss of speciﬁcity and
afﬁnity (Butler et al., 1993; Conroy et al., 2009). Hence, small re-
combinant antibody fragments, nucleic acid aptamers, and con-
strained and unconstrained short peptides, inter alia, have been
investigated as alternative capture molecules in biosensors (Evans
et al., 2008; Johnson et al., 2008; Zeng et al., 2012; Yang et al.,
2014; Zhou et al., 2014). Recently, we demonstrated the detection
of anti-myc tag antibodies (Raina et al., 2015) by EIS employing
capture molecules constructed from a small, robust and highly
stable synthetic protein scaffold that displays two short peptide
loops (Tiede et al., 2014). These short and highly constrained
peptide loops were selected to provide the selective afﬁnity to the
target molecule. Here, we extend the use of these novel scaffold-
based capture proteins to detect human IL-8 in full serum with
sub-pg/ml sensitivity using a label-free EIS-based sensor.2. Experimental section
2.1. Materials
Human IL-8 protein (ab73858) was purchased from Abcam, UK,
diluted with deionised water (18.2 MΩ cm) to a stock concentra-
tion of 200 μg/ml and stored at 20 °C. Synthetic antibody mi-
metic proteins with high afﬁnity to human IL-8 were selected viaphage display. The capture protein coding region was sub-cloned
into pET11 and recombinant protein was puriﬁed as previously
described (Tiede et al., 2014; Raina et al., 2015). Monothiol-alkane-
PEG-acid (HS-C11-(EG)6-OCH2-COOH) was purchased from Pro-
chimia, Poland. Horse serum was sourced from Invitrogen, New
Zealand, stored at 4 °C, and ﬁltered with 0.22 μm ﬁlters supplied
by Fisher Scientiﬁc, UK, prior to use. Sodium acetate was pur-
chased from Fisher Scientiﬁc. 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS)
and ethanolamine-HCl were purchased from GE Healthcare as a
part of an amine coupling kit. All other reagents and solvents,
unless stated otherwise, were purchased from Sigma Aldrich, UK.
Deionised water (18.2 MΩ cm) from a Millipore water puriﬁcation
system was used to prepare all buffer solutions. Bare SPR disks
with 48 nm of gold deposited on a layer of titanium, and compa-
tible with the Autolab ESPRIT SPR system, were purchased from
Metrohm Autolab, UK. Double junction Ag/AgCl reference ceramic
wick electrodes were sourced from VWR, UK.
2.2. Methods
2.2.1. Gold electrode cleaning
2.2.1.1. SPR studies. SPR gold disks were sonicated for 10 min in a
solution of 1% Triton X-100 in 100 mM NaOH, followed by 20 min
sonication in 200 proof molecular biology grade ethanol.
2.2.1.2. EIS studies. The gold electrodes used in the EIS studies,
provided by Evatec AG (Switzerland), were fabricated by evapor-
ating 20 nm of titanium and 80 nm gold onto a polished silicon/
silicon oxide wafer. The evaporated electrodes (1 cm2) were soni-
cated twice in acetone for 10 min and subsequently rinsed in
ethanol (200 proof).
2.2.2. Functionalisation of gold electrode with monothiol-alkane-
PEG acid SAM
The cleaned electrodes were rinsed with ethanol (200 proof)
prior to immersion in 1 mM ethanolic solution of carboxylic-acid-
terminated monothiol-alkane-PEG with 5% acetic acid. The elec-
trodes were incubated for 48 h at room temperature to allow the
assembly of a well-ordered self-assembled monolayer (SAM) on
the gold electrode. Afterwards, the electrodes were rinsed in
ethanol (200 proof) to remove excess molecules from the surface
and dried under a stream of nitrogen.
2.2.3. Immobilisation of the synthetic binding proteins on the SAM
layer
Electrodes functionalised with SAMs were mounted either in
an electrochemical cell for EIS studies or on a hemi-cylinder for
SPR measurements. To attach the synthetic binding proteins on
the SAM surface, the exposed area of the gold electrodes intended
for EIS measurements was rinsed with 100 mM 2-(N-morpholino)
ethanesulfonic acid (MES) buffer at pH 5.5, while for SPR-based
studies, the buffer was injected into the channel until a stable SPR
baseline was established. The carboxylic acid group of the SAM
layer was activated by exposing the electrode surface for 15 min to
a 1:1 mixture of 400 mM EDC and 100 mM NHS in 100 mM MES
buffer at pH 5.5.
The activated surface was then washed with 100 mM MES
buffer pH 5.5 to remove excess EDC/NHS from the surface followed
by rinsing with 10 mM acetate buffer at pH 5.5. Subsequently, the
surface was incubated for 30 min in the same buffer containing the
capture proteins at a concentration of 10 μg/ml. Finally, the surface
was exposed to a 1 M ethanolamine solution at pH 8.5 for 15 min
to quench any residual activated sites on the SAM layer.
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SPR experiments were performed in a two-channel Autolab
ESPRIT system (Autolab, Netherlands). The temperature of the
system was kept constant at 22 °C using a recirculating water bath
(R-150 Grant) connected to the SPR system.
2.2.4.1. Capture protein attachment. Optimal pH conditions for the
immobilisation of the synthetic non-antibody binding proteins
were established in 10 mM buffer solutions with a range of pHs
from 8 to 4.5. Phosphate buffer was used for pH 8.5–6, while for
pH 5.5–4.5, acetate buffer was employed. The gold electrode
functionalised with the SAM and mounted in a SPR ﬂow channel
was subjected to a buffer solution, starting with the highest pH i.e.
8.5. Binding proteins at 10 μg/ml in the same buffer were then
allowed to adsorb onto the surface for 400 s, while monitoring the
SPR signal. After each pH, the surface was regenerated with 10 mM
NaOH solution to remove the adsorbed binding proteins com-
pletely from the SAM. A new baseline was then established with
the buffer solution at another pH and the experiment repeated.
2.2.4.2. IL-8 detection. The gold electrodes with immobilised
binding proteins and blocked with ethanolamine were washed
with 100 mM phosphate buffer at pH 7 and a stable baseline was
established. IL-8 proteins diluted in 100 mM phosphate buffer pH
7 to a concentration of 1 μg/ml was applied to one of the channels,
while the second channel was used as a reference. The SPR signal
was monitored to detect binding of the IL-8 proteins to the surface.
2.2.5. Electrochemical impedance spectroscopy (EIS)
All EIS experiments were carried out in a three-electrode
electrochemical cell, comprising a double junction Ag/AgCl as re-
ference electrode, a platinum wire as a counter electrode and a
cleaned gold surface as the working electrode. The working elec-
trode was 2 mm in diameter and its distance from the reference
electrode during EIS measurements was about 5 mm. The re-
ference electrode was stored in a 3.5 M solution of KCl when not in
use. The electrochemical cell was placed in a Faraday cage to
minimise interference from any external electrical noise.
The gold electrodes were mounted in an electrochemical cell.
The electrodes were then washed twice in the electrolyte (100 mM
phosphate buffer pH 7 or serum, as appropriate) before 800 μl and
500 μl of fresh buffer and serum, respectively, was added. Elec-
trochemical impedance measurements were performed using a
BioLogic VSP potentiostat and EC-lab software provided with the
system was used to record and analyse the response data. All EIS
measurements were performed by applying a 30 mV sinusoidal ac
potential to the working electrode at frequencies from 100 kHz–
50 mHz (7 points/decade), unless stated otherwise, superimposed
on a dc potential between 0 mV and 80 mV, and 0 mV and 100 mV,
for measurements in buffer and serum, respectively. Before pro-
ceeding with the biosensing EIS measurements, the SAM-func-
tionalised electrodes were subjected to an EIS measurement at a
200 mV dc potential for ten cycles in order to transform a well
packed SAM into a leaky capacitor (Boubour and Lennox, 2000)
and to reach a stable EIS baseline. All potentials are reported vs Ag/
AgCl. EIS scans were repeated for ﬁve cycles.
2.2.6. Differential scanning calorimetry
The thermal stability of the non-antibody binding proteins as
well as the empty scaffold protein was assessed using a VP-DSC
MicroCalorimeter (GE Healthcare). Each sample was dialysed
against 1 phosphate buffered saline (PBS) pH 7.4 and diluted to a
concentration of 0.5 mg/ml. After degassing, the heat capacity of
the samples was measured from 10 °C to 120 °C at a scan rate of
90 °C/h.2.2.7. Bio-layer interferometry (BLI)
The binding kinetics between the non-antibody binding pro-
teins and human IL-8 was measured using a bio-layer inter-
ferometer (BLItz, Pall Fortebio). The measurements were carried
out using the Ni-NTA dip and read biosensors. A baseline was ﬁrst
established in 1 PBS buffer by measuring the response of the
sensor for 30 s. Binding proteins at 100 mg/ml concentration in 1
PBS were then immobilised on the sensor via their C-terminus
eight-histidine tags for 2 min. To obtain the association phase, the
sensor was rinsed with 1 PBS for 30 s, before being exposed to
different concentrations of IL-8 proteins in 1 PBS buffer for
5 min. Subsequently, 1 PBS buffer was applied and the dis-
sociation phase was recorded. The data analysis was carried out
using ProFit software (Quansoft, Switzerland).
2.2.8. Mass spectrometry
Non-antibody binding proteins in 1 PBS were buffer ex-
changed into 50 mM ammonium acetate using Zeba spin columns
(7k MWCO; Thermo Scientiﬁc) and samples of 20 ml containing
20 mM proteins were analysed on a Synapt HDMS (Waters UK Ltd.)
electrospray mass spectrometer.3. Results and discussion
3.1. IL-8 speciﬁc capture molecules
We have previously developed non-antibody-based binding
molecules employing small scaffold proteins (Mw∼12 kDa) that
display two short, constrained peptide loops, which provide high
and speciﬁc afﬁnity for the target protein. A detailed discussion of
these antibody mimetics is given elsewhere (Tiede et al., 2014;
Raina et al., 2015). In brief, a highly diverse antibody mimetic li-
brary where both binding loops were randomised was generated
(diversity 41010), and phage display was employed to select
binders with afﬁnity for human IL-8. Four clones with high afﬁnity
for human IL-8 proteins were identiﬁed and initially assessed via a
phage ELISA assay (Fig. S1). The binding protein showing the
strongest afﬁnity to IL-8 was chosen as the capture molecule for
the EIS biosensor.
The IL-8-speciﬁc binding protein was characterised in detail,
and its molecular mass determined using mass spectroscopy was
found to be 13.52 kDa, agreeing with the expected value (Fig. S2).
A high stability of the capture molecule is of importance for bio-
sensors to ensure sensor stability and device shelf-life, and so
differential scanning calorimetry (DSC) measurements were car-
ried out to assess stability. The heat capacity Cp is shown in Fig. S3
as a function of temperature between 20 °C and 110 °C. A distinct
melting peak at Tm¼82 °C was observed for the IL-8 binding
proteins, demonstrating the very high thermo-stability. For com-
parison, the heat capacity of the empty scaffold (Tm¼101 °C) is
shown in the same ﬁgure. The reduced melting temperature of the
binding protein compared to the empty scaffold is likely to be due
to the changes in the structure of the scaffold protein where the
binding loops were introduced. Similar observations were re-
ported for binding proteins designed to capture anti-myc tag an-
tibodies (Raina et al., 2015).
The limit of detection that can be achieved by a label-free
biosensor depends on the afﬁnity between the capture molecule
and the target protein, and hence the performance of the IL-8
binding molecule was investigated using bio-layer interferometry
(BLI). The binding proteins were attached to a pre-activated Ni-
NTA BLI sensor tip at a concentration of 10 mg/ml via the eight-
histidine tag of the protein located at the C-terminal. The sensor
was then exposed to different concentrations of human IL-8 pro-
teins in PBS pH 7.0 for 5 min each to ensure saturation was
Fig. 1. (a) Binding response at equilibrium of human IL-8 binding to non-antibody capture molecule immobilised onto the sensor surface detected using bio-layer inter-
ferometry. The solid line shows the least-square ﬁt of the Langmuir binding isotherm to the linearised data. Inset: linearised form of binding data where the y-axis R/C
corresponds to the sensor response at equilibrium (R) divided by human IL-8 concentration (C), and the x-axis to the sensor response at equilibrium (R). (b) Sensogram
showing change in the SPR angle of the sensor functionalised with the binding protein to both human IL-8 and BSA from the 100 mM phosphate buffer pH 7.4 baseline.
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association, the sensor was exposed to PBS and the dissociation
phase was recorded.
Fig. 1a shows the response of the sensor at equilibrium as a
function of IL-8 concentration. The solid line shows a least-square
ﬁt of the Langmuir binding isotherm Req¼CBmax/(CþKD) to the
response of the sensor at equilibrium, Req, in linearised form
(Scatchard plot, shown in the inset), where C is the concentration
of the human IL-8, Bmax the sensor response at saturation, and KD
the dissociation constant. The ﬁt revealed a KD of 35710 nM,
demonstrating the high afﬁnity of the binding protein to human
IL-8. This compares well with the afﬁnities of two native human
IL-8 receptor proteins CXCR1 and CXCR2 with reported solution-
phase KD of 5 nM and 2.5 nM, respectively (Nasser et al., 2007), in
particular when taking into account that the IL-8 binding proteins
reported here were attached to a solid surface which generally
leads to an order of magnitude increase of KD compared to solu-
tion-phase KD.
3.2. Sensing element
The different components of the sensing element of the bio-
sensor developed in this work are shown in Fig. 2, and comprise a
gold electrode coated with a SAM of monothiol-alkane-PEG-acid
(HS-C11-(EG)6-OCH2-COOH). The PEG moieties of the SAM yield a
highly anti-fouling surface which prevents any non-speciﬁc
binding of unwanted molecules to the sensor element from the
sample ﬂuid (Herrwerth et al., 2003). The non-antibody capture
protein speciﬁc to IL-8 is covalently attached to the SAM via car-
boxylic acid groups pre-activated with EDC and NHS.Fig. 2. Schematic illustration of the biosensor assembly. A monothiol-alkane-PEG acid SA
then activated with EDC/NHS to which the non-antibody capture proteins are covalently
the sensor surface is challenged with ﬂuids containing human IL-8 protein and the elecTo establish optimal coupling conditions for immobilising the
capture proteins onto the SAM surface, a range of SPR experiments
were carried out at different pH. Binding proteins at a con-
centration of 10 μg/ml in sodium acetate and phosphate buffers of
pH between 4.5 and 8 were applied to the SAM-functionalised
gold electrodes, and the change in the SPR angle was monitored
(Fig. S4). Only a very small change in SPR angle (∼60 m°) was
observed when the binding proteins were in buffers at pHZ7.5.
Upon lowering the pH, the response gradually increases and then
starts to saturate at pHr5.5 where changes in the SPR angle of
about 430 m° were measured. We note that the onset of the sa-
turation coincides with the pH at which the overall charge of the
IL-8 capture molecule becomes positive.
For all following sensor experiments, the activated carboxylic
acid SAM-functionalised gold electrodes were exposed to 10 mg/ml
of IL-8 capture protein in 10 mM sodium acetate buffer, pH 5.5,
and the residual activated carboxylic acids were capped with
ethanolamine. To test the speciﬁcity of the sensor element, fully
functionalised surfaces were exposed to human IL-8 proteins at
1 μg/ml in 100 mM phosphate at pH 7 and the change in the SPR
angle was monitored in real-time. A 66 m° shift from the baseline
(100 mM phosphate buffer pH 7) was recorded at saturation. This
contrasts with the response of less than 2 m° that was observed
when the sensor was challenged with 5 mg/ml bovine serum al-
bumin (BSA), clearly demonstrating the speciﬁcity of the binding
protein for human IL-8 (Fig. 1b). The full SPR sensogram, including
the capture molecule immobilisation on the SAM functionalised
electrode and subsequent detection of human IL-8, is shown in Fig.
S5a.M is ﬁrst assembled on a gold electrode. The carboxylic acid groups of the SAM are
attached. Following deactivation of residual activated acid sites with ethanolamine,
trochemical impedance of the sensor is monitored.
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spectroscopy
EIS is a powerful tool for the label-free detection of target
proteins. For biosensors employing molecular layers at the inter-
face between the sensor electrode and the sample ﬂuid, the
electrochemical impedance is governed by the impedance of the
sensor–electrolyte interface, which is generally dominated by ca-
pacitive contributions. The interface impedance is the sum of the
contributions from the SAM, the capture protein layer, the internal
Stern layer, and the diffused Gouy and Chapman layer that extends
into the electrolyte solution (Rampi et al., 1998; Bard and Faulkner,
2000). Changes to any of these components, such as binding of the
biomarkers to the capture molecules, results in an overall change
in impedance, which is then reﬂected in the change of the am-
plitude Z and the phase θ of the sensors' electrochemical im-
pedance. For sensors where a highly packed SAM with low leakage
and a high dielectric constant is employed at the interface, the
binding of the ligand to the capture molecules predominately
changes the capacitance associated with the Stern layer, which
forms the basis of capacitive electrochemical sensors (Berggren
et al., 2001). This change in capacitance is generally attributed to
the displacement of water molecules and solvated ions further
away from the sensor surface (Berggren et al., 1998). In contrast,
for sensors employing less densely packed SAMs, defects such as
pinholes in the SAM can contribute signiﬁcantly to the overall
impedance, and in fact any change in the density or size of the
defects can lead to substantial changes in the electrochemical
impedance (Zaccari et al., 2014). Upon binding of target proteins to
the capture molecules attached to the SAM, the local environment
of the SAM may change, potentially leading to changes in SAM
defects. This in turn leads to a change in the electrochemical im-
pedance, which can be measured.
The phase of the impedance, θ(ƒ), has previously been shown to
be a reliable and sensitive measure to monitor the binding of
target proteins to the sensor surface as well as changes in the
sensor interface (Evans et al., 2008; Raina et al., 2015). Hence,
changes in the phase of the impedance, Δθ(ƒ), were employed
here for the detection of human IL-8 proteins, but also for evalu-
ating the assembly of monothiol-alkane-PEG SAMs on the gold
electrode, and subsequent immobilisation of the capture proteins
during sensor fabrication.
3.3.1. SAM assembly
The monolayer quality was assessed by EIS and spectra were
taken between 100 kHz and 50 mHz at Ag/AgCl potential. TheFig. 3. EIS Bode plots showing (a) the phase θ(ƒ) after the formation of the monothiol-a
(b) the phase θ(ƒ) after immobilisation of the non-antibody capture molecules on the SAM
EIS measurements were conducted in 100 mM phosphate buffer at pH 7 and the data s
shown in Fig. S7.average phase of the impedance calculated from ﬁve different
scans is shown in Fig. 3a. A dominating capacitive behaviour of the
SAM was observed at low frequencies where θ(ƒ) is approaching
90°, indicative of a densely packed SAM formed on the electrode
that very effectively blocks the current. On average, the phase of
the impedance at 0.1 Hz, θ(ƒ)0.1 Hz, was 8472°.
Non-zero dc potentials Zþ150 mV were reported to induce
pinholes into a SAM and thus to transform a well-packed SAM into
a leaky capacitor with correspondingly increased θ(ƒ) (Boubour
and Lennox, 2000). Comparable results were obtained in recent
work where an increased θ(ƒ) was found at low frequencies at
higher dc potential, and the EIS sensors were found to be more
sensitive with increased θ(ƒ) (Raina et al., 2015). A similar increase
in the low-frequency phase of the electrochemical impedance was
observed here when the dc potential of SAM functionalised elec-
trodes was raised from þ0 mV to þ80 mV. This is shown in
Fig. 3a, where the average of θ(ƒ)0.1 Hz taken across ﬁve devices
increased to 8172° at þ80 mV from 8472° recorded at
0 mV dc bias.
3.3.2. Capture protein immobilisation
Following the SAM assembly, capture proteins were im-
mobilised on the activated carboxylic acid SAM surface, followed
by quenching of residual sites with ethanolamine. Similar to
above, the phase of the electrochemical impedance was measured
at 0 mV and þ80 mV dc potential from 100 kHz to 50 mHz. The
phase of the sensor was found to decrease towards 90° at fre-
quencies below 1 Hz, with a difference of almost 2° at 0.1 Hz. In
contrast, the spectrum above 1 Hz was not affected. The results are
shown in Fig. 3b (80 mV dc bias) and Fig. S6 (0 mV dc bias), where,
after the attachment of the capture proteins, θ(ƒ)0.1 Hz decreased
from 83.3° to 84.8°, and from 85.5° to 86.6°, at 80 mV and
0 mV dc bias, respectively. This suggests that the capture proteins
and ethanolamine form a densely populated layer, resulting in an
increase in the capacitive behaviour of the sensor.
3.3.3. IL-8 detection
Before exposing the sensor devices to different concentrations
of human IL-8 protein spiked into horse serum, the sensors were
incubated in blank serum for 15 min to establish a baseline. 50 μl
of the serum in the electrochemical cell was then replaced with
serum containing human IL-8 to achieve the desired concentra-
tion. The phase of the electrochemical impedance θ(ƒ)0.1 Hz was
immediately measured at a þ100 mV dc offset potential and then
after 15 min of IL-8 incubation, and the difference in phase with
respect to the baseline, Δθ(ƒ)0.1 Hz, was determined. Multiplelkane-PEG acid SAM on the gold electrode at 0 mV and þ80 mV dc potential, and
in comparison to the SAM only at a dc offset potential of þ80 mV vs Ag/AgCl. The
hown represent the average θ(ƒ) of ﬁve EIS scans. Corresponding Nyquist plots are
Fig. 4. (a) EIS sensogram showing the change in phase from the baseline at 0.1 Hz, Δθ(ƒ)0.1 Hz, of the sensor response vs IL-8 concentration between 9 fg/ml and 900 ng/ml (a
representative Nyquist plot for one of the devices is shown in Fig. S8). Inset: effect of IL-8 incubation time on Δθ(ƒ)0.1 Hz from the baseline, with measurements taken
immediately and after 15 min of incubation. (b) EIS sensogram showing the response of the sensor when exposed to IL-8 free serum and BSA-spiked serum. The inset shows
the variance of the sensor signal over time. All EIS scans were performed at a dc offset of þ100 mV vs Ag/AgCl.
R. Sharma et al. / Biosensors and Bioelectronics 80 (2016) 607–613612devices were fabricated and exposed to different starting con-
centrations of IL-8; the Δθ(ƒ)0.1 Hz response of a typical sensor
device is shown in Fig. 4a.
The performance of the sensor was investigated across a con-
centration range between 9 fg/ml and 900 ng/ml. A small change
in θ(ƒ)0.1 Hz of 173 m° from the serum baseline was observed at an
IL-8 concentration of 9 fg/ml (1 fM), and when the concentration
was increased by 10-fold, a small further increase in θ(ƒ)0.1 Hz of
70.6 m° was recorded. Above this IL-8 concentration, the sensor
recorded signal was comparatively high, and a linear response
versus logarithm of IL-8 concentration across the entire con-
centration range was observed with a slope of 220.4 m°/decade.
For biomarker detection in complex clinical samples such as
serum it is important for the sensor devices to show no or minimal
response to any molecules other than the desired target proteins.
To test the non-speciﬁc response, the devices were exposed to
horse serum that was not spiked with human IL-8 protein, and the
phase of the electrochemical impedance θ(ƒ)0.1 Hz was measured at
a þ100 mV dc offset potential immediately, and 15 min after the
serum injection. 50 μl of the total serum volume was then re-
placed with fresh serum and the sensor device incubated for a
further 15 min before measuring the change in phase, Δθ(ƒ)0.1 Hz.
This was repeated for an additional three cycles and the average
Δθ(ƒ)0.1 Hz taken from two independent devices is shown in the
inset of Fig. 4b. We note that the measured phase ﬂuctuated by
less than 60 m° over the course of 45 min, demonstrating that the
device is highly stable across the time-scale relevant for the EIS
sensors discussed here.
The non-speciﬁc binding of the sensor was further examined by
subjecting it to serum samples spiked with BSA at different con-
centrations. A change in θ(ƒ)0.1 Hz of 286 m° was observed when
the device was exposed to 9 pg/ml of BSA, which increased further
by 30 m° upon further incubation for 15 min. For a higher con-
centration of BSA, i.e. 900 pg/ml, a change in θ(ƒ)0.1 Hz of 400 m°
was observed after 15 min incubation (Fig. 4b), which is sig-
niﬁcantly lower than the signal measured for the same con-
centration of human IL-8. A similarly small change in the θ(ƒ)0.1 Hz
was observed when the sensor was exposed to human interleukin-
6 (IL-6) at concentrations between 10 fg/ml and 100 ng/ml (θ
(ƒ)0.1 Hzo350 m° at 100 ng/ml; Fig. S9), demonstrating the speci-
ﬁcity of the sensor.
4. Conclusions
We have demonstrated a label-free biosensor based on EIS to
detect human IL-8 protein spiked into full serum at clinicallyrelevant concentrations with very high sensitivity and a time-to-
result of 15 min. The sensor employs a small and robust antibody
mimetic as the capture molecule, which was selected from a
highly diverse library using phage display. The capture molecule
was found to be highly selective for human IL-8 with a KD of
35710 nM, and was found to be very stable with a melting
temperature of 82 °C.
The change in the phase of the electrochemical impedance at
0.1 Hz, Δθ(ƒ)0.1 Hz, was used as the measure to quantify the binding
of IL-8 proteins to the surface-immobilised non-antibody capture
molecules, and a detection limit of around 90 fg/ml of IL-8 in full
serum was demonstrated. Furthermore, a linear relationship be-
tween Δθ(ƒ)0.1 Hz and the logarithm of the IL-8 concentration in
serum was observed between 900 fg/ml and 900 ng/ml, i.e. over
six orders of magnitude.
These ﬁndings are of particular signiﬁcance for POC diagnostics,
where high sensitivities and detection limits well below basal
clinical levels, as well as short time-to-results, are required to
enable early diagnostics.Data statement
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